Medical/Pharmaceuticals
Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA
--Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food and Drug Administration (FDA) to conduct a Phase Ib study in patients with monkeypox virus disease --Preclinical studies show that ASC10-A, active metabolite of double prodrug ASC10, has potent ant...
2022-11-16 08:10
4183
YC and Alchemist-backed Segmed Raises $5.2M Funding Round and Launches Medical Real World Imaging Platform
PALO ALTO, Calif., Nov. 16, 2022 /PRNewswire/ -- Segmed - a cloud-based real-world imaging platform that accelerates innovation in healthcare by simplifying access to medical data - announced the closing of a$5.2 million seed+ funding round led by Nina Capital, with participation from iGan Partne...
2022-11-16 03:03
4591
Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022
XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipmen...
2022-11-15 21:19
4054
Reistone Biopharma's oral Ivarmacitinib Meets Primary Endpoint in Phase III Study for Atopic Dermatitis
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- Reistone Biopharma (Reistone), a leading biotech company focused on development of innovative medicines for immune and inflammation diseases, todayannounced positive results from a Phase III study – QUARTZ3 (NCT04875169) evaluating the efficacy and safet...
2022-11-15 21:00
3623
Island to present at World Antiviral Congress 2022
MELBOURNE, Australia, Nov. 15, 2022 /PRNewswire/ -- Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to advise that CEO and Managing Director, DrDavid Foster will present at the World Antiviral Congress 2022 inSan Diego, USA which ...
2022-11-15 21:00
3436
Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis
ANNAPOLIS, Md., Nov. 15, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-m...
2022-11-15 20:30
2870
HanAll Biopharma Reports Third Quarter 2022 Results and Provides Business Update
* Financial results for Q3 2022 ended with revenue of KRW 29.6 billion with continued growth in the pharmaceutical division driven by product portfolio expansion and strong sales in major products * R&D expenses for the quarter increased by 63%, reflecting the preparation of a Phase 3 study i...
2022-11-15 20:00
2193
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue
* Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue topsKRW 40.4 billion * Fexuclue, a new drug released last July, shows steep growth in market share in Korea * Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastrit...
2022-11-15 20:00
2457
EDAN Took Its Solutions up a Notch at MEDICA 2022
DUSSELDORF, Germany, Nov. 15, 2022 /PRNewswire/ -- Edan Instruments Inc. (300206.SZ) demonstrated its range of latest innovations at MEDICA, the premiere global medical trade show held atDusseldorf, Germany, from Nov. 14 to 17, 2022. Five new products are presented to bring a huge surprise to mor...
2022-11-15 18:26
2677
Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer
* An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cancer in Phase I/II TORCH-2 Study of ATG-008 (onatasertib) in combination with toripalimab, regardless of PD-L1 status * Study builds on promising results of Phase II TORCH monotherapy study in HBV+ p...
2022-11-15 16:51
3000
Nona Biosciences Announces Attendance at PEGS Europe 2022
CAMBRIDGE, Mass., Nov. 15, 2022 /PRNewswire/ -- Nona Biosciences (a wholly-owned subsidiary of HBM Holdings, HKEX: 02142) announced that the Company is attending the 14th Protein and Antibody Engineering Summit (PEGS) in Barcelona, Spain, November 14-16, 2022. The booth is located at #54. Frank ...
2022-11-15 15:57
3083
Striving Together, Upgrading the Biopharma Industry - International Biopharma Industry Week Shanghai 2022 Kicks Off
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- On November 14, the opening ceremony of the second "International Biopharma Industry Week Shanghai" (hereinafter referred to as the "IBIWS 2022") took place in the Shanghai Zhangjiang Science Hall. Themed on "Striving Together, Upgrading the Biopharma Indus...
2022-11-15 14:17
3545
WuXi Vaccines Establishes New Vaccines CDMO Facility in China
SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Va...
2022-11-15 12:45
3325
HARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATION
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Nov. 14, 2022 /PRNewswire/ -- Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned subsidiary, Nona Biosciences, to provide next-generation antibody and biotherapeutic solutions to partners from discovery to IND. T...
2022-11-15 12:19
2728
Peng Lei: RCEP countries to be first stop on NeuroXess' international expansion roadmap
SHANGHAI, Nov. 15, 2022 /PRNewswire/ -- The 2nd Asia Summit on Global Health, co-organized by the Hong Kong SAR Government and the Hong Kong Trade Development Council, got under way inHong Kong on November 10. The event brought together specialists in research and medicine from around the world a...
2022-11-15 11:34
2833
Biotheus has entered into a license and collaboration agreement with Hansoh Pharma for its EGFR/MET bispecific antibody in the Greater China territory
ZHUHAI, China, Nov. 14, 2022 /PRNewswire/ -- Biotheus Inc., a clinical-stage biotech company focused on the discovery and development of biologics for oncology and inflammatory diseases, announced today that they have entered into a collaboration agreement with Hansoh Pharmaceuticals, for Biotheu...
2022-11-15 11:16
2968
C&R Research, the Largest Korean CRO, Expands Partnership with Medidata to Enhance Their Clinical Operations
* C&R Research is the only CRO that authorized to Rave CTMS in Korea * Sponsors targeting global markets will manage clinical operations with these solutions that effectively support multinational clinical trials. SEOUL, South Korea, Nov. 15, 2022 /PRNewswire/ -- Medidata, a Dassault Systèmes ...
2022-11-15 11:00
4153
Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity
ROCKVILLE, Md. and SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2022-11-15 08:00
4945
Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy
-- NDA acceptance takes Everest closer to making this first-in-disease treatment available for primary IgAN patients inChina -- China is home to the largest patient base for IgAN with estimated 5 million people with the disease and currently there is no approved treatment in the country -- Nefe...
2022-11-15 08:00
5147
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa * Early customers include GP offices and other community-based healthcare settings * Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly ...
2022-11-14 23:24
3495
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
26431
ZD Energy Unveils Overseas Smart Energy Solutions in Thailand, Leveraging Local Manufacturing and Scenario-Based Capabilities to Support the Country's Energy Transition
2026-11-06 22:12
15354
SILVERSEA MARKS HISTORIC OPENING OF THE CORMORANT AT 55 SOUTH, THE SOUTHERNMOST HOTEL ON EARTH, OFFERING A NEW GATEWAY TO ANTARCTICA
2026-11-07 01:05
14822
OceanaGold Reports Third Quarter 2026 Results
2026-11-05 06:52
14632